Myeloma Crowd Radio: Craig Cole, MD, University of Michigan

At the University of Michigan, Dr. Craig Cole is working on a collaboration with the MMRC to perform genomic sequencing on 500 hundred relapsed and refractory myeloma patients over a two year period. The goal is to share each patient's genomic profile to identify patient-specific treatment options. The study will be open at 11 myeloma academic centers to begin, with more to open in the future. The tissue samples collected at these centers are shipped to the University of Michigan Comprehensive Cancer Center, which then evaluates the alterations of 1700 genes. The study aims to find the specific mutations that are "actionable," or that have a drug that can be used. The study goal is to make myeloma treatment more precise for a disease that varies widely from patient to patient. 

Thanks to our episode sponsor, Takeda Oncology